



## The Current Development of Flavivirus Vaccines, Diseases Control and Epidemiological Situation

Guest Editors:

**Dr. Satoru Arai**

Center for Surveillance,  
Immunization, and  
Epidemiologic Research,  
National Institute of Infectious  
Diseases, Tokyo, Japan

**Prof. Dr. Tsutomu Omatsu**

Center for Infectious Disease  
Epidemiology and Prevention  
Research, Faculty of Agriculture,  
Tokyo University of Agriculture  
and Technology, Tokyo 183-8509,  
Japan

Deadline for manuscript  
submissions:

**31 March 2025**

### Message from the Guest Editors

Dear Colleagues,

The Flavivirus genus consists of viruses that can cause serious diseases, such as Dengue, Zika, West Nile, yellow fever, Japanese encephalitis, and tick-borne encephalitis. This Special Issue focuses on sharing the latest developments and vaccine trends in Flavivirus infection. We welcome your original research articles, reviews, and perspectives on novel experimental vaccine candidates, vaccine strategies, immune responses, and concerns or optimizations related to vaccine strategies. We also welcome related topics on the epidemiological situation and trends of Flavivirus infection.

Dr. Satoru Arai

Dr. Tsutomu Omatsu

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)